Novartis announced the FDA granted accelerated approval for Fabhalta® (iptacopan), making it the first and only complement inhibitor to treat adult patients with primary IgA nephropathy (IgAN). This approval is based on results from the Phase III APPLAUSE-IgAN study in which Fabhalta achieved a favorable safety profile and a clinically meaningful and statistically significant 38% reduction in proteinuria vs. placebo. This marks the first approval from Novartis' renal pipeline, which also includes atrasentan and zigakibart for the treatment of IgAN. Read More: https://lnkd.in/eaTs_z5G #Nephrology #IgAN #Fabhalta #Novartis #FDAapproval
Spherix Global Insights
Market Research
Exton, PA 4,055 followers
Invest In Intelligence That Delivers
About us
Spherix Global Insights is a leading provider of market research, business intelligence and advisory services to the global life sciences industry. The company’s unique service offerings are powered by deep therapeutic knowledge, the Spherix Network specialty physician panel, and commercially relevant analyses to enable strategic decision-making by our valued customers. A trusted advisor and industry thought leader, Spherix Global Insights provides specialized market expertise in six (6) focused therapeutic areas including: dermatology, gastroenterology, nephrology, neurology, rheumatology and ophthalmology.
- Website
-
https://www.spherixglobalinsights.com/
External link for Spherix Global Insights
- Industry
- Market Research
- Company size
- 51-200 employees
- Headquarters
- Exton, PA
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Nephrology Insights, Neurology Insights, Rheumatology Insights, Custom Consulting for Specialty Pharma, Healthcare Research, Primary Research, Dermatology Insights, Independent Insights, Gastroenterology Insights, Biopharma, Market Research, Marketing Analytics, Business Intelligence, Big Data, Physician Surveys, Renal Insights, Global Data, Biologics, Multiple Sclerosis, Ophthalmology, Life Sciences, and Immunology Insights
Locations
-
Primary
720 Constitution Drive
2nd Floor
Exton, PA 19341, US
Employees at Spherix Global Insights
-
Pete Kuz
Providing Healthcare Insights that drive Strategy
-
Alissa Algarin
A Leader in Strategic Analytics and Business Intelligence | Passionate about better understanding who we serve, how we market, and how we leverage…
-
Frank Franzino
Insights Director, Neurology at Spherix Global Insights
-
Dan Barton
Chief Executive Officer at Spherix Global Insights
Updates
-
Spherix Global Insights reposted this
Spherix Global Insights thanks all of our industry partners who met with us at the Alzheimer's Association International Conference (AAIC). Great conference in 2024! If we missed you, please reach out as our Alzheimer's market research is moving at hyper-speed this summer.
-
-
August is Psoriasis Action Month, a time to take meaningful steps in supporting those with psoriasis, a chronic autoimmune condition affecting around 100 million people globally. This condition often causes red, scaly patches on the skin and is linked to other health issues like cardiovascular disease and diabetes. By taking action, we can drive improvements in diagnosis, treatment, and support, making a real difference for individuals managing psoriasis. To learn more visit: https://lnkd.in/dUE9Bjs #ThisIsPsoriasis #Psoriasis #PsO #Dermatology
-
-
Roche announced the European Commission has approved VABYSMOⓇ (faricimab-svoa)® (faricimab) for the treatment of visual impairment due to retinal vein occlusion (RVO). This follows positive results from Phase III studies showing Vabysmo's efficacy in improving vision and reducing retinal fluid, similar to aflibercept. Additionally, up to 60% of patients could extend treatment intervals to three or four months. Vabysmo is also approved in the US and Japan for RVO and is available in nearly 100 countries for nAMD and DME. Read more: https://lnkd.in/dQHNi_ND #RVO #Vabysmo #nAMD #DME #Ophthalmology
-
-
Partners STADA Group and Calliditas Therapeutics announce the European Commission full approval for Kinpeygo® for the treatment of adults with primary immunoglobulin A nephropathy (IgAN), making it the first fully approved disease-modifying treatment for IgAN in the EU. This approval results in a broader label for patients with primary IgAN and is based on data from the Phase 3 NeflgArd clinical trial, where Kinpeygo met its eGFR endpoints with high statistical significance. Additionally, the EC confirmed Kinpeygo’s status as a rare disease orphan drug, which subjects it to 10-year market exclusivity until 2032. Read More: https://lnkd.in/e78V5Hhg #Nephrology #IgAN #Kinpeygo #STADA #Calliditas
-
-
AbbVie received European Commission approval for SKYRIZI for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. The approval of SKYRIZI is based on two Phase 3 clinical trials, INSPIRE and COMMAND, in which both primary and key secondary endpoint results were achieved, and the safety profiles were consistent between the two trials and with other approved indications. Read more: https://lnkd.in/eRkCHnhq #AbbVie #SKYRIZI #UlcerativeColitis #Gastroenterology
-
-
SUN PHARMA announced the FDA approval of Leqselvi™ (deuruxolitinib), an oral JAK inhibitor for the treatment of adults with severe alopecia areata (AA). This approval is based on Phase 3 clinical trials THRIVE-AA1 and THRIVE-AA2, where the primary endpoint was met, with more than 30% of patients taking LEQSELVI experiencing 80% or more scalp hair coverage at 24 weeks. Read More: https://lnkd.in/eC9X3Mbw #Dermatology #AlopeciaAreata #Alopecia #FDAapproval #Leqselvi
-
-
On this World Sjögren's Day, we honor the strength and resilience of those living with Sjögren's Syndrome, an autoimmune disease that affects millions globally. This condition, primarily characterized by dry mouth and dry eyes, often occurs alongside other autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. By raising awareness, we can improve diagnosis, treatment, and support for patients. To donate towards furthering Sjögren's research, click here: https://lnkd.in/d2T-cUa #Rheumatology #WorldSjögrensDay #SjögrensSyndrome #AutoimmuneDisease
-
-
Fierce Pharma highlighted Spherix's research on the launch of Takeda's Eohilia in EoE treatment. Over 50% of surveyed physicians have prescribed Eohilia, with trial rates comparable to Dupixent at a similar stage. Projections indicate an increase in market share within six months. To gain more insights, read the full article here: https://lnkd.in/eWCRWwxt #Gastroenterology #EosinophilicEsophagitis #EoE
-
Join us on July 22 for World Brain Day as we unite to raise awareness advocating for early detection and management of neurological disorders, including multiple sclerosis (MS), migraine, Alzheimer's disease and epilepsy. Let's come together to prioritize brain health and create a healthier future for all. To learn more, click here: https://lnkd.in/dQiTq4FU #Neurology #WorldBrainDay #Alzheimers #epilepsy #migraine #multiplesclerosis #dementia
-